These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36840231)

  • 21. Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation.
    Anastassova N; Aluani D; Kostadinov A; Rangelov M; Todorova N; Hristova-Avakumova N; Argirova M; Lumov N; Kondeva-Burdina M; Tzankova V; Yancheva D
    Neural Regen Res; 2021 Nov; 16(11):2299-2309. PubMed ID: 33818516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of transcription factor SP1 produces neuroprotective effects through decreasing MAO B activity in MPTP/MPP
    Yao L; Dai X; Sun Y; Wang Y; Yang Q; Chen X; Liu Y; Zhang L; Xie W; Liu J
    J Neurosci Res; 2018 Oct; 96(10):1663-1676. PubMed ID: 30004136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemical components and monoamine oxidase B inhibition activities from the tubers of
    Ayeni EA; Ma C; Zhang YM; Fan WQ; Liao X
    Nat Prod Res; 2023; 37(17):2916-2923. PubMed ID: 36301745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors.
    Tzvetkov NT; Stammler HG; Neumann B; Hristova S; Antonov L; Gastreich M
    Eur J Med Chem; 2017 Feb; 127():470-492. PubMed ID: 28107736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
    Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
    Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melatonin Analogues Potently Inhibit MAO-B and Protect PC12 Cells against Oxidative Stress.
    Elkamhawy A; Woo J; Gouda NA; Kim J; Nada H; Roh EJ; Park KD; Cho J; Lee K
    Antioxidants (Basel); 2021 Oct; 10(10):. PubMed ID: 34679739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety.
    de Beer AD; Legoabe LJ; Petzer A; Petzer JP
    Bioorg Chem; 2021 Sep; 114():105130. PubMed ID: 34225162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.
    Hitge R; Smit S; Petzer A; Petzer JP
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127188. PubMed ID: 32299731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.
    Chung JY; Lee JW; Ryu CH; Min HK; Yoon YJ; Lim MJ; Park CH
    J Neurosci Res; 2015 Aug; 93(8):1267-78. PubMed ID: 25711470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular aspects of monoamine oxidase B.
    Ramsay RR
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():81-9. PubMed ID: 26891670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action.
    Elkamhawy A; Kim HJ; Elsherbeny MH; Paik S; Park JH; Gotina L; Abdellattif MH; Gouda NA; Cho J; Lee K; Nim Pae A; Park KD; Roh EJ
    Bioorg Chem; 2021 Nov; 116():105352. PubMed ID: 34562673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties.
    Yelekçi K; Karahan O; Toprakçi M
    J Neural Transm (Vienna); 2007; 114(6):725-32. PubMed ID: 17401533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancing monoamine oxidase B inhibitory activity via chiral fluorination: Structure-activity relationship, biological evaluation, and molecular docking study.
    Wang Z; Yi C; Chen K; Wang T; Deng K; Jin C; Hao G
    Eur J Med Chem; 2022 Jan; 228():114025. PubMed ID: 34871839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The monoamine oxidase inhibition properties of C6-mono- and N3/C6-disubstituted derivatives of 4(3H)-quinazolinone.
    Qhobosheane MA; Legoabe LJ; Petzer A; Petzer JP
    Bioorg Chem; 2019 Apr; 85():60-65. PubMed ID: 30599413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxicity of two triterpenoids from Nigella glandulifera.
    Tian Z; Liu YM; Chen SB; Yang JS; Xiao PG; Wang L; Wu E
    Molecules; 2006 Sep; 11(9):693-9. PubMed ID: 17971743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
    Nagatsu T; Sawada M
    J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indanones as high-potency reversible inhibitors of monoamine oxidase.
    Mostert S; Petzer A; Petzer JP
    ChemMedChem; 2015 May; 10(5):862-73. PubMed ID: 25820651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.